Rosemont Offers $2.70 Per Share for Aytu BioPharma in $56 Million Acquisition

CryptoWire
Today at 11:29am UTC

By Ben Hansel, Senior Financial Editor 247MarketNews

DENVER, Colo. (247MarketNews) — Aytu BioPharma (NASDAQ:AYTU) agreed to a $2.70-per-share cash acquisition by UK-based Rosemont Pharmaceuticals, giving shareholders a substantial premium while providing Rosemont with an established US specialty pharmaceutical platform.

Aytu’s latest quarterly results show growth in its emerging antidepressant business, but continued weakness in its ADHD portfolio.

The November 16 agreement values the transaction at approximately $56 million on a fully diluted basis, according to Aytu. The $2.70 offer represents a 41.1% premium to the company’s 30-day volume-weighted average price and a 51.7% premium to its November 13 closing price. Aytu’s board unanimously approved the transaction.

The deal is structured as a cash tender offer followed by a second-step merger. Rosemont’s acquisition subsidiary must receive valid tenders representing at least a majority of Aytu’s outstanding common shares, alongside satisfying other conditions. The agreement also addresses outstanding warrants, including requirements for certain warrants to be exercised or terminated. The transaction provides for the same $2.70-per-share consideration in the subsequent merger, excluding shares for which appraisal rights are properly exercised.

Aytu’s directors, executive officers and certain shareholders affiliated with Nantahala Capital Management and Stonepine Capital Management signed tender and support agreements.

The acquisition announcement arrived alongside Aytu’s fiscal 2027 first-quarter results, providing an interesting snapshot of the business Rosemont is buying. Revenue increased 6.9% year over year to $14.8 million, while EXXUA, Aytu’s treatment for major depressive disorder, generated $4.9 million in revenue. EXXUA prescriptions increased 32.5% sequentially to 4,400 for the quarter. However, ADHD portfolio revenue declined to $7.7 million from $13.2 million a year earlier, reflecting reduced promotional spending and generic competition. Aytu also reported a $3.9 million quarterly net loss and $25.5 million in cash at September 30.

Rosemont specializes in oral liquid medicines, particularly formulations designed for patients who have difficulty swallowing conventional tablets. Backed by private equity firm Inflexion, the company sees the acquisition as an opportunity to expand its US presence and combine complementary pharmaceutical development, manufacturing and commercialization capabilities.

The next important milestone is the formal commencement of the tender offer. Rosemont intends to file its Schedule TO within 10 business days, with Aytu expected to file its Schedule 14D-9 recommendation statement. Closing is anticipated by the end of December 2026, although the agreement allows for termination if the transaction has not closed by February 14, 2027, subject to the agreement’s provisions.

About the Author

Ben Hansel is a financial and business writer with a background in business, sales, and finance. He graduated from the University of Texas at El Paso. His professional and educational background informs his coverage of financial markets, corporate developments, economic trends and the broader forces shaping the market.

Important Editorial Note: 247MarketNews highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication.  Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.